BEIJING--(BUSINESS WIRE)--BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company’s collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-283, a second-generation BRAF inhibitor candidate currently in Phase 1 development. The milestone triggers a US$ 5 million payment from Merck to BeiGene.
Help employers find you! Check out all the jobs and post your resume.
